Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 1.00 |
| ▸ | GIPR | P48546 | 20/20 | 1.00 |
| ▸ | GLP1R | P43220 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647223 | 0.94 | GCGR (0.89) | GCGRGIPRGLP1R | |
| SCHEMBL2651831 | 0.89 | GCGR (0.81) | GCGRGIPRGLP1R | |
| SCHEMBL2665493 | 0.89 | GCGR (0.80) | GCGRGIPRGLP1R | |
| SCHEMBL2665608 | 0.89 | GCGR (0.79) | GCGRGIPRGLP1R | |
| SCHEMBL2665487 | 0.88 | GCGR (0.79) | GCGRGIPRGLP1R | |
| SCHEMBL9071699 | 0.87 | GCGR (0.78) | GCGRGIPRGLP1R | |
| SCHEMBL2665610 | 0.87 | GCGR (0.77) | GCGRGIPRGLP1R | |
| SCHEMBL6288856 | 0.85 | GCGR (0.74) | GCGRGIPRGLP1R | |
| SCHEMBL9071780 | 0.85 | GCGR (0.75) | GCGRGIPRGLP1R | |
| SCHEMBL2665528 | 0.85 | GCGR (0.77) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | claimed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | claimed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.